[Ip-health] Press links on OTA and lack of Bayh-Dole safeguards in COVID-contracts
pfehlner at revisiontx.com
Fri Jul 3 08:34:33 PDT 2020
If the Federal Government never conditions funding on some direct benefit to the public in terms of pricing or access, it doesn’t make much difference whether the OTA or Bayh-Dole provisions apply to a grant.
Conversely, the Government is free to condition grants on any terms it wants. March-in rights provide a specific process, but there is always the option of negotiating up front and, failing that, eminent domain. None of these matter so long as the first condition is the government’s policy.
> On Jul 2, 2020, at 11:31 AM, Claire Cassedy <claire.cassedy at keionline.org> wrote:
> Below are links to some of the press coverage on the Other Transaction
> Authority agreement issue and the COVID-related OTAs.
> Christopher Rowland. "Trump administration makes it easier for drugmakers
> to profit from publicly funded coronavirus drugs, advocates say."
> Washington Post. July 1, 2020.
> Bob Herman. “Federal government weakened its march-in rights for
> coronavirus drugs.” Axios. July 1, 2020.
> Sharon Lerner. “The Trump Administration is waiving the public’s right to
> affordable coronavirus treatments.” The Intercept. July 1, 2020.
> Ed Silverman and Nicholas Florko. “Some U.S. government contracts for
> Covid-19 research could skirt affordable pricing laws.” STAT. July 1, 2020.
> Jonathon Gardner. "Federal coronavirus contracts dodge pricing oversight,
> advocacy group says." BioPharma Dive. July 1, 2020.
> KEI's press advisory available here:
> Claire Cassedy
> Knowledge Ecology International
> 1621 Connecticut Avenue NW
> Suite 500
> Washington, DC 20009
> Tel.: 1.202.332.2670
> Ip-health mailing list
> Ip-health at lists.keionline.org
More information about the Ip-health